Table 4 Medicines offering the greatest potential savings (to UNRWA central tender prices)
Medicine | Therapeutic group | Comparator | Potential annual savings in USD |
|---|---|---|---|
Neutral sol./isophane insulin 30/70 100 IU/ml 10 ml vial | Antidiabetic | GCC price | $ 467,624 |
Amoxicillin + clavulanic acid 500 + 125 mg tab | Antimicrobial | GCC price | $ 393,109 |
Benzylpenicillin benzathine 1/1.2MIU vial | Antimicrobial | GCC price | $ 243,822 |
Gliclazide 80 mg tab | Antidiabetic | JPD price | $ 210,907 |
Azithromycin 200 mg/5 ml suspension | Antimicrobial | JPD price | $ 144,489 |
Total | $ 1,459,951 (9.5% of General Fund expenditure on medicines) | ||